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Abstract An implantable transducer for monitoring the
flow of Cerebrospinal fluid (CSF) for the treatment of
hydrocephalus has been developed which is based on
measuring the heat dissipation of a local thermal source.
The transducer uses passive telemetry at 13.56 MHz for
power supply and read out of the measured flow rate. The
in vitro performance of the transducer has been character-
ized using artificial Cerebrospinal Fluid (CSF) with
increased protein concentration and artificial CSF with
10% fresh blood. After fresh blood was added to the
artificial CSF a reduction of flow rate has been observed in
case that the sensitive surface of the flow sensor is close to
the sedimented erythrocytes. An increase of flow rate has
been observed in case that the sensitive surface is in contact
with the remaining plasma/artificial CSF mix above the
sediment which can be explained by an asymmetric flow
profile caused by the sedimentation of erythrocythes having
increased viscosity compared to artificial CSF. After
removal of blood from artificial CSF, no drift could be
observed in the transducer measurement which could be
associated to a deposition of proteins at the sensitive
surface walls of the packaged flow transducer. The flow
sensor specification requirement of +−10% for a flow range
between 2 ml/h and 40 ml/h. could be confirmed at test
conditions of 37°C.
Keywords Neurosurgery . Hydrocephalus . Calorimetric
flow sensor . Biocompatible packaging . Passive telemetry
1 Introduction
Hydrocephalus is one of the most common congenital
disorders of the central nervous system. Hydrocephalus
may also develop after birth and may be caused by
secondary damage to the brain caused by hemorrhage,
stroke, infection, tumor, or traumatic injury. Normal
Pressure Hydrocephalus NPH, in which the pressure of
CSF may not be elevated, is a form of chronic hydroceph-
alus that typically occurs in adults who are 60 years and
older. It is characterized by clinical symptoms of dementia,
gait disturbance (i.e., difficulty walking), and urinary
incontinence (Black et al. 1985). While the symptoms
associated with NPH can intensify over time if the
condition is left untreated, if treated properly, the dementia
associated with NPH can be reversed.
Hydrocephalus occurs when there is an imbalance
between the amount of CSF that is produced and the rate
at which it is absorbed. Cerebrospinal Fluid (CSF) is
produced by secretory cells of the choroid plexus at a rate
of approximately 20 ml per hour, circulates through the
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ventricular system and is finally absorbed into the venous
system via the superior sagittal sinus. The occurrence of
hydrocephalus in newborn children is about 1 out of 500–
2,000 (Murshid et al. 2000; Persson et al. 2007).
The treatment of hydrocephalus requires the implanta-
tion of a catheter for fluid drainage. Per year, more than
100,000 shunt valves are implanted worldwide. However,
malfunctioning of the shunt catheter cannot be excluded
which might lead to severe complications especially for
children (Oikonomou et al. 1999).
Shunt blockage occurrence ranges from 20% to 30%
within the first year after implantation. In order to diagnose
a shunt system, an invasive procedure is often required and
as with any invasive procedure, the risk to the patient is
increased. When the diagnostic gives questionable results,
the shunt system will be replaced and this sometimes leads
to unnecessary surgical procedures that further impact the
patient and increases the cost of patient care.
In the case of NPH, improvement of patient conditions
by implantation of a shunt valve has been achieved in 30–
50% of patients (Vassilouthis 1984). However, the implan-
tation of a shunt valve to divert excessive CSF carries a
complication rate of approximately 40% (Vanneste et al.
1992; Vanneste 2000) in case of NPH of which 20% are
severe (Vanneste 2000), mostly due to over-drainage
(Larsson et al. 1991).
In order to monitor in-vivo intracranial conditions,
micromachined capacitive pressure sensors with telemetric
communication have been developed (Ko et al. 1981;
Munshi et al. 1998; Ginggen et al. 2008).
In contrast to pressure monitoring, flow sensing would
provide a direct method to monitor patency of the shunt
valve as well as to capture physiological relevant variations
of CSF flow. Furthermore, there is a need for intelligent
shunts that are able to dynamically adjust to varying
operating conditions and thereby reduce the number of
shunt revisions a patient has to undergo. Implantable flow
sensors for monitoring of hydrocephalus would represent
one essential component of future intelligent shunt valves.
However, flow sensing of CSF is currently done using
MRI methods (Linninger et al. 2007) which are costly,
time-consuming and not readily accessible on short notice.
Another method to get information of CSF flow in the
ventricular system is by using computational fluid dynam-
ics methods (CFD). Kurtgluoclu et al. have shown that by
combination of anatomic, velocimetric and magnetization
modulated MRI scans with CFD simulations, it is possible
to reconstruct the CSF flow field in the third brain ventricle
and the aqueduct of Sylvius (Kurtcuoglu et al. 2007).
CSF flow from the peritoneal end of a ventriculo-
peritoneal (V-P) shunt was detected by means of Doppler
ultrasonography. Although in general, clear CSF is not
ultrasonically visible, the presence of choroid plexus debris
was assumed to provide ultrasonic contrast in some cases
(Sgouros et al. 1996).
The first objective of this study was to develop a
calorimetric flow transducer, which can be positioned close
to the shunt valve and implanted in the patients. The sensor
must be fully biocompatible and communicate flow
measurements to the clinician by passive telemetry. The
second aim was to perform in-vitro test of this flow sensor
to quantify the effect of CSF proteins deposition on the
general performance of the device and on the accuracy of
flow measurements.
The flow transducer allows an improved long-time
monitoring of the functioning of the valve and allows a
better understanding of the flow of CSF under varying
physiological conditions of the patient. An improved
management of hydrocephalus shunted patients will be
possible by avoiding conditions of over- and underdrainage
of CSF.
2 Materials and methods
The micromachined implantable transducer with the
streamline integrated fluid channel is placed into the
peritoneal or atrial catheter close to the Hydrocephalus
shunt valve by gluing it into a silicone housing which will
be sealed with silicon lips at the edge. A polymer plate will
be applied to hold the transducer in place. An external
reader supplies the transducer with energy and reads the
data from the implanted transducer by passive telemetry.
The external reader is coupled to a Bluetooth transceiver
which transmits the transducer data to an external computer
or battery powered PDA for data storage, -display and
processing (Fig. 1).
2.1 Transducer description
The implantable transducer consists of three main parts: a
calorimetric flow sensor based on a thermal anemometer
principle (Lammerink et al. 1993; Mayer et al. 1997), a
microcontroller and a RF section (Fig. 2). The flow sensor
(Sensirion AG, Stäfa, Switzerland) is realized on a CMOS
silicon chip that contains the sensor as well as all necessary
electronics to treat the sensor signal (ADC, linearization,
amplification, temperature compensation, calibration mem-
ory) (Mayer et al. 2004). The sensors have been calibrated
using water as medium with a specification requirement of
+−10% for a flow between 2 ml/h and 40 ml/h.
The flow channel is formed by sandwiching 2 glass
wafers. The bottom wafer of 1.4 mm thickness has a
rectangular channel with dimensions 0.9 mm × 0.9 mm
formed by dicing saw cutting to which a 0.1 mm thick top
glass wafer is bonded.
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In order to provide the implant with energy and to read
out the measured flow rate, RF passive telemetry is used at
a RF frequency of 13.56 MHz (Neukomm et al. 2003;
Schnakenberg et al. 2000). The RF section of the implant is
responsible for extracting energy for the implant, for
transmitting the level of RF induced voltage to the micro-
controller (Silabs C8051F300) as well as for modulating the
FSK signal for communication with the external reading
unit. Modulation frequencies at 109 kHz for a logic 0 and
117 kHz for a logic 1 are applied to the load modulating
circuit at V1 by the microcontroller (Fig. 3).
In order to reduce the energy dissipated in the implant,
the modulation pulse width of the microcontroller had to be
minimized. Since the microcontroller only generates FSK
modulation frequencies with 50% duty cycle, an additional
capacitor C11 was used to adjust the modulation pulse with.
If the pulse width is selected too large, too much energy is
dissipated in the load resistor R3 and the telemetric reading
range is decreased. However if the pulse width is too small,
the FSK signal is too weak and the modulation cannot be
detected by the external reading unit. It was found that a
duty cycle of about 15% to 20% gives optimal results.
In order to minimize the height of the implant, a diode
D1 is used in the load modulator instead of an inductivity
as used in common passive telemetry systems. The energy
drawn from the magnetic field supplied by the external
reading unit is stored in a large capacitance C12 in order to
ensure stable power supply of sensor and microcontroller
during active load modulation.
The load resistor R3 was chosen as small as possible to
achieve a maximal load modulation amplitude. On the other
side, the minimal value of R3 was limited by the maximum
collector current of V1.
The power consumption of the CMOS flow sensor was
measured to be 16.3 mW in measuring mode at a supply
voltage of 3.3 V. Taking into account the power consump-
tion of the ultra-low power microcontroller of 2.87 mW at a
supply voltage of 3.3 V, the minimal energy needed for
supply of the implant is 19.17 mW. As the output voltage of
the RF-DC varies according to the distance between
antennas of reading unit and implant as well as external
power supplied, the voltage of the RF-DC converter is
passed to a voltage regulator (TPS715A33) which regulates
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Fig. 2 Components of the implantable calorimetric flow transducer.
The height of the encapsulated implant is 4.5 mm. Bottom left: Bottom
view of the packaged sensor showing the rectangular flow channel.
Bottom right: Top view of the packaged flow sensor
External reader
Implantable 
transducer 
Graphical user interface
Hydrocephalus shunt valve 
Shunt catheter 
Fig. 1 Overview of the implant-
able transducer for flow sensing
of hydrocephalus including im-
plantable transducer with calori-
metric flow sensor and passive
telemetry for power supply and
data communication via external
reader. Flow data can be dis-
played on the reader as well as
on an external computer via
Bluetooth
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the supply voltage input to the microcontroller and the
CMOS flow sensor to 3.3 V.
2.2 External reading unit
The external reading unit is used to supply the implant with
energy and to acquire the flow measurement data. Using a
maximum transmission power of 3 W of the external
reading unit, the induced voltage at the RF-DC converter of
the transducer implant could reach voltages up to 16 V with
reader antenna and implant at a distance of 2 mm and
voltages up to 10 V at a common working distance of
17 mm between antennas of external reader and transducer,
which, at a distance of 17 mm, would lead to a power
dissipation of up to 60 mW and a temperature increase in
the implant from 37°C up to 41.2°C.
In order to reduce excessive heating of the implant, the
induced voltage of the RF-DC converter is measured by the
microcontroller and transmitted to the external reader where
its transmission power is adjusted accordingly (Fig. 4). This
way, the maximum RF-DC voltage is kept constant at a
voltage of 5 V and the total energy dissipated in the implant
sums up to 29.05 mW leading to a measured temperature
increase in the implant from 37°C to 39°C which
corresponds to the maximum allowable temperature in-
crease of an active implant in operating conditions
[International Standards Organisation (ISO) 14708-1
(2000)].
One of the main problems of the use of passive telemetry
in implants for simultaneous energy supply and data
communication is the controlled power-up of the implant
as the microcontroller and flow sensor need a minimal slew
rate of the supply voltage when started which cannot be
reached if the RF field of the external reader is approached
only slowly to the implant. This problem has been solved
by software in the external reader where a microcontroller
verifies the incoming data packages. If no valid data
packages are demodulated by the reading unit or the
incoming data has transmissions errors, it is assumed that
the provided RF field is not strong enough to feed the
sensor and microcontroller. In this case the RF field is
switched off for 20 ms and on for 300 ms periodically until
the RF field at the implant has sufficient amplitude to
provide a sufficiently steep slope for the supply voltage.
This process also treats problems if the connection breaks
down for other reasons like no proper alignment of
antennas.
2.3 Packaging of the transducer and biocompatibility
One of the key features of the transducer is the calorimetric
flow measurement which is done through the borosilicate
glass substrate of 100 um thickness. Using this configura-
tion, the temperature sensors and the heaters are not directly
exposed to the body fluids. Therefore, no coating or
passivation of the sensors and heaters is needed and
Fig. 3 Transducer telemetry electronics. Green: Loop antenna and impedance matching. Red: RF-DC Converter. Purple: Load modulator. Blue:
DC supply
Powersupply
Voltage
Antenna
Antenna
Energy
Data
measurement
RF Emitter Adjust RFPower
Demodulate
Data
Fig. 4 Energy supply and com-
munication between external
reader and implanted transducer.
In order to minimize the power
dissipated in the implant, the RF
power of the reader is adjusted to
keep the supply voltage at the
input of the voltage regulator of
the implanted transducer constant
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electrical feed-throughs to the fluidic chamber are avoided.
In that way, a highly reliable and long-term biocompatible
implant could be realized which is especially important as
the transducer will remain inside the body for up to 10 years
or even longer (Bork 2007).
In order to provide a leak-tight packaging of the implant,
a low-temperature brazing process is used to join a
borosilicate glass base plate and a borosilicate glass cap
(Ginggen 2003) (Fig. 5). The Base plate which includes the
flow channel and carries the PCB with the transducer
electronics as well as the glass cap are metallised by
sputtered Ti(100 nm)/Au(2,000 nm) rings. An eutectic
SnInAg alloy (Sn77.25 In20 Ag2.8, melting temperature
184°C) brazing ring with a thickness of 50 µm is used to
join the metallisations of glass cap and glass base plate.
The brazing rings are cut using a Nd:YAG nanosecond
laser (pulse duration<25 ns) at 355 nm using a laser spot
diameter of 20 μm and a power of 2 W.
However, the brazing ring used to encapsulate the
implant modifies the inductivity of the implant antenna by
mutual inductive coupling. In addition, it represents a short
circuited metallic conductor which, in close proximity to
the implant antenna, induces additional eddy currents in the
brazing ring where part of the RF energy is be dissipated. In
order to minimize the energy dissipated in the brazing ring,
the distance of the implant antenna to the brazing ring has
been increased to a distance of 0.7 mm (Figs. 6 and 7).
Taking a maximal power of the external reading unit of 3 W
and an energy of 29.05 mV dissipated in the implantable
transducer at a voltage of the RF-DC converter of 5 V, a
maximal allowed damping of the antenna system responsi-
ble for RF energy transmission of −20dB can be deduced.
In Fig. 7, the RF energy transfer characteristics of the
reader and transducer antenna system is shown. At a
distance of 0.7 mm between brazing ring and lower edge
of the implant antenna, a maximal allowed damping of
−20dB leads to a maximal communication distance be-
tween external reader antenna and implant antenna of about
37 mm. This distance is sufficient for a reliable communi-
cation with the implant as the implant will be implanted
subcutaneously into the skull behind the ear.
2.4 In-vitro characterization of the implantable flow
transducer
2.4.1 Test liquids for characterisation of protein adsorption
The clinical significance of elevated protein levels in
cerebrospinal fluid (CSF), its impact on implants like
shunt valves, and the comparative tolerance of specific
shunt systems to an elevated CSF protein level has been
the subject of discussion for many years. The consensus
view being until recently is that to shunt a patient whose
CSF protein level was high was to risk shunt blockage
and infection. Protein deposition from “normal” CSF is
slow, but it was shown that a range of proteins
(vitronectin, fibronectin and fibrinogen) was eventually
deposited on the inner surface of shunts immediately after
insertion (Lundberg et al. 1999).
However, it was shown that the thin protein film that
accumulates on shunt catheters is not sufficient to cause
obstruction. The major protein in this film was shown to be
albumin (Brydon et al. 1998).
Calorimetric flow sensors with temperature sensing and
heating elements attached to the walls of the fluid channel
are sensitive to modifications of the sensing surface area.
A potential protein or blood component adsorption
especially during the first days after implantation with a
electronic compounds GlascapAntenna 
1
2
AdhesivePCBBraze ring 
x 
4
3
Fig. 6 Positioning of the transducer antenna in the implant to
minimize influence from brazing ring. In order to reach an overall
height of the implantable transducer of 4.5 mm, the total height
available for the electronics inside the implant capsule (2) is limited to
2 mm. The maximal height of the antenna and the electronic
components mounted on the Printed Circuit Board (PCB) is 1 mm
(1). Taking into account the thickness of the adhesive of about
0.2 mm, the distance between antenna and brazing ring (x) can be
adjusted to 0.7 mm max. leaving a tolerance of 0.1 mm (the bottom
glass substrate and the top glass cap have a thickness of 1.5 mm (3)
and 1 mm (4))
A
B
D
E
C
F
Fig. 5 Packaging of the implantable transducer. Implant assembly. A:
Glass cap, B: Electronics with antenna, C: Flow sensor, D: Braze ring,
E: Glass base plate, F: Flow channel
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risk of elevated protein concentration and blood within the
CSF could have an influence on the flow sensor response.
In order to investigate the sensor performance under worst
case situations, the flow rate of the sensor was measured using
elevated protein concentration and blood content in CSF.
The composition of normal CSF is close to that of
ultrafiltrate of plasma and has a protein concentration of
less than 0.5% of that of plasma (Kuschinsky 1996). The
normal adult range of protein content in the CSF ranges
between 0.15 g/l and 0.45 g/l (Davson and Segal 1996;
Critchley et al. 1972).
However, CSF protein content varies with age and is
known to decline over the first few months of life (Widell
1958). Elevated protein content in CSF may be indicative
of a pathologic process and levels above 1.0 g/l in neonates
and 0.35 g/l in preadolescent children can be reached
(Wong et al. 2000).
In order to take into account even pathologic levels of
protein concentrations in CSF and to accelerate the protein
absorption, artificial CSF with a protein concentration that
was increased by a factor of 10 to reach 2 g/l was prepared
according to Table 1 and used in the in-vitro tests.
Due to patients who have hydrocephalus as a result of a
haemorrhagic event such as periventricular haemorrhage in
the premature neonate, or subarachnoid haemorrhage in the
adult, CSF containing a profile of proteins different from that
of “normal” CSF must be taken into consideration as well.
For the testing, the following solutions were used:
– artificial CSF with 2 g/l protein (Albumin from human
serum)
– artificial CSF with 2 g/l protein (Albumin from human
serum) and 10% fresh blood
– sterile water with 0.65% Sodium azide as reference
solution
In order to simulate a potential protein deposition that
might affect the sensor function after e.g. a subarachnoid
haemorrhage, fresh human blood was drawn from a vein
and added immediately to the warmed artificial CSF
solution in order to avoid clotting. As the mixture tends to
Fig. 7 Transfer characteristics
of the transducer telemetry
without braze ring (blue and
red) as well with braze ring of
the transducer. At a distance x of
0.7 mm between brazing ring
and lower edge of the implant
antenna (see also Fig. 6), a
damping of −20dB leads to a
maximal communication
distance of about 37 mm
Chemical Name Formula Conc. in CSF [g/L]
Sodium chloride NaCl 8.660
Potassium chloride KCl 0.224
Calcium chloride dihydrate CaCl2-2H20 0.206
Magnesium chloride hexahydrate MgCl2-6H20 0.163
Sodium phosphate monobasic monohydrate NaH2PO4-H20 0.027
Di-Sodium hydrogen phosphate heptahydrate, acs Na2HPO4-7H20 0.214
Sodium Azide 0.1 M Solution N3Na 5 g or 0.77 ml
D-(+)-Glucose C6H12O6 0.600
Urea CH4N2O 0.201
Albumin (from human serum) 2.000
Gamma-globulin from human blood 0.015
Table 1 Composition of artificial
Cerebrospinal fluid
612 Biomed Microdevices (2010) 12:607–618
degrade after about 24 hrs at 37°C due to break up of
erythrocytes, the solution was changed daily.
2.4.2 Fluidic test setup
The fluidic circuit for characterization of the implantable
flow sensors consists of a tubing pump which pulls the test
liquids artificial CSF, artificial CSF with 10% fresh blood
and sterile water with 0.65% Sodium azide as reference
solution through three parallel fluidic circuits (Fig. 8).
Sodium azide is used as a preservative for sterile water to
prevent growth of bacteria. The test setup was kept in an
oven at 37°C. The scale reading was taken in parallel and
the flow was calculated by taking the start reading and the
end reading of the balance. Taking the flow measurement of
the scale as the point of reference, a relative flow rate in %
was calculated by taking
flow rate flow sensorð Þ  flow rate scaleð Þ
flow rate scaleð Þ  100
In order to simulate a continuous use of the flow sensor
during the test period of 26 days, the heater of the flow
sensor was periodically turned on for 5 minutes and then
turned off for 10 minutes in between the scale measure-
ments. The test period of 26 days was chosen base on the
observation of Baird et al. that perfusion of hydrocephalus
valves with solutions of dilute whole blood showed effects
on the perfusion pressure of the valves due to adsorption
effects after within their test period used of 14 days (Baird
et al. 2002).
The tubing diameter of the fluidic test system has been
selected to be 1.02 mm.
The peristaltic pump has been used in a mode pulling
fluid through sensors in order to reduce pulsation ripples in
the fluidic system created by the rollers of the peristaltic
pump. Once a day, the measurements of the sensors have
been compared to a scale where a measurement time of
180 s and a sampling frequency of 10 Hz has been used.
For that purpose, the fluidic channel to the scale which
normally is disconnected from the pumping circuit by a
two-way valve, was primed using a syringe pump. Then,
each of the three fluidic circuits was interrupted subse-
quently and opened to the scale. In order to evaluate the
flow rate by the scale measurement, the weight of the liquid
was linearly fitted as a function of time.
3 Results and discussion
In Fig. 9 the relative flow rate for all sensors for a test period
of 26 days is shown as the difference between the flow
sensor measurement and the comparative scale measure-
ment. Within those 26 days the flow rate has been varied
from the nominal flow of 20 ml/h down to 2.5 ml/h and up
to 50 ml/h in order to characterize the relative flow rate of
the flow sensors at different flow rates within the operating
range. It can be seen that there is no apparent drift in any of
the three fluidic circuits, especially when only comparing the
beginning and the end of the testing where the 20 ml/day
flow rate was tested.
The average of all relative flow rates (261 values) shown
in Fig. 9 is offset by −5.4% for a test temperature of 37°C.
As the flow sensors have been calibrated at a temperature of
22°C, the influence of temperature on the difference
between the scale measurements and the flow sensor
measurements was evaluated.
For that purpose, the oven containing the fluidic setup
has been adjusted to 22°C and 37°C and 3 sensors have
been characterized at 2 different flow rates of 5 ml/h and
10 ml/h at temperatures 22°C and 37°C. The temperature
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3
Fig. 8 Test setup for in-vitro
characterisation of the implant-
able flow transducer. Only one
fluidic circuit is shown
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offset of the relative sensor flow rates at 37°C is about
6.3% compared to the relative sensor flow rates at 22°C.
A temperature compensation of the offset of −5.4% at
37°C with the temperature offset of +6.3% leads to a
compensated average of all relative flow rates of +0.9%.
The reference liquid containing sensors (brown in Fig. 9)
as well as the CSF/protein containing sensors (yellow in
Fig. 9) are maintaining essentially the same difference
between sensor and scale measurements throughout the test.
Only the sensors of the fluidic circuit that had tempo-
rarily 10% fresh blood added to it (red in Fig. 9) show an
increase of relative flow rate of ∼20% to ∼25% during the
time the blood is present.
In order to test the dependency influence of the sensor
reading with respect to the sensor position/orientation the
original setup has been modified so that the sensors could
be mounted in different positions/orientations as described
in Fig. 10. For this test, a constant flow rate of 20 ml/h was
used. After each position/orientation change of the sensor, a
time of 15 min was used to allow for a stabilization of the
fluidic system before measurement.
Looking at the data of Fig. 11 during the time when 10%
fresh whole blood was present in the artificial CSF, one can
see that for the two measurements where the sensors are
mounted horizontally with the sensors on the top of the
flow channel, the adding of fresh blood changed the
average relative flow rate from an average flow rate
without blood of −7.4% (“Horizontal sensor UP”) to
+12.3% (”Horizontal sensor Blood UP 1”) and to +7.0%
(“Horizontal sensor Blood UP 2”). After blood was
removed from the artificial CSF, the sensor reading came
back to an average relative flow rate of −7.4%. For the
position- and orientation depending measurements shown
in Fig. 11, a nominal flow rate of 20 ml/h was used.
In case the sensor is flipped and is located below the
flow channel (“Horizontal Sensor Blood DOWN” in
Fig. 11), the relative flow rate is decreased from an
average flow rate without blood of −7.8% to an average of
−60.7%.
Finally, the sensors were mounted in a vertical position
with the flow either going up- or downwards giving
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Fig. 9 Relative flow rate of the
implantable calorimetric flow
sensor as a function of time. In
flow circuit 3 (sensors 31, 32,
33), artificial CSF was tempo-
rarily replaced by artificial
CSF + 10% fresh blood as
indicated by the dotted lines
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Fig. 10 Description of the position and orientation of the flow sensor
with respect to the flow used for measurements shown in Fig. 11
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average relative flow rates of −9% (“Vertical Flow Blood
UP”) and −2.6% (“Vertical Flow Blood DOWN”). After the
CSF/blood mixture has been removed and replaced by
artificial CSF, the average sensor measurements of sensors
31, 32 and 33 in Fig. 11 show a relative flow rate of −7.5%
which corresponds to the relative flow rate before blood was
added to the fluidic system. The configurations “Vertical
Flow Blood UP” “Vertical Flow Blood DOWN” should
show the same flow speed as in both cases no sedimentation
of erythrocytes should occur. The observed difference of
relative flow rates can be explained by the fact that, the
liquid in the flow channels was still not homogeneously
mixed which could also be confirmed visually.
Comparing the relative flow rates before and after the
blood was added/removed in Fig. 9, even the flow sensors
in the fluidic circuit with artificial CSF and 10% blood
don’t exhibit a drift. Furthermore when looking at Fig. 9
one can see that there is no major influence on the relative
flow rate when tested between 2.5 ml/day and 50 ml/day.
All measured differences between sensor and scale meas-
urements for all sensors remain within 0% to −10% except
sensor 32 with ∼−12% during the 50 ml/day measurement.
This deviation might be explained by a misaligned fluidic
connection it was found to be very important to have a
laminar flow at the sensor location which is depending on
the fluidic connection and the flow rate used.
The data of sensors 11, 12, 13 (deionized H2O with
0.65% sodium azide), and of sensors 21, 22 and 23
(artificial CSF with 2 g/l proteins) in Fig. 11 show that
when no blood is present in the fluid the influence of the
position/orientation on the sensor reading can be neglected.
All data points for any of the positions/orientations of these
sensors are within a range of −2% to −8%.
The observed effects of flow rate when blood is added to
artificial CSF can be explained by the settling of the heavier
erythrocytes on the bottom of the flow channel due to the
low flow rate used. This sedimentation could be observed
visually in the channel tubing and can basically influence
the performance of the anemometric flow sensor via a
change of thermal conductivity of the medium close to the
heater and sensors or via a change of viscosity and thus
change of the speed of flow close to the sensing surface.
As shown in Fig. 12, the response of the sensor strongly
depends on the thermal conductivity of the liquid which is
in contact with its heater and temperature sensors. The
calibration curves of the calorimetric sensor for water with
a thermal conductivity of (κWater=0.6 W/(m·K) and of
methanol with a lower thermal conductivity of (κMethanol=
0.21 W/(m·K) shows a raw sensor signal of −8,200 a.u. for
water compared to −2,760 a.u. for methanol. As the sensor
used for the measurement shown in Figs. 9 and 11 uses an
internally stored calibration curve for water, the use of a
liquid with a thermal conductivity different from water
would impact the sensor reading accordingly.
As the thermal conductivity κ of whole human blood
with 0.49 W/(m·K) is smaller than that of CSF with
0.63 W/(m·K) (Neff 2005), the thermal conductivity of the
sediment in contact with the sensor in case “Horizontal
Sensor Blood DOWN” in Fig. 11, will be reduced. The
thermal conductivity of the mixture of artificial CSF with
plasma in contact with the sensor in case of “Horizontal
Sensor Blood UP 1/2” is close to that of CSF as the thermal
conductivity of plasma is close to CSF (κPlasma=0.57 W/
(m·K), (Balasubramaniam and Bowman 1977)) and there-
fore the sensor signal should not be influenced by thermal
properties of the liquid in this position of the sensor.
However, the relative flow rate increased by an average of
+17% compared to the scale reference measurement with
the sensor on the top of the flow channel which indicates an
increased velocity of the liquid.
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Fig. 11 Relative flow rate depending on the position and orientation
of the flow sensor with respect to the flow channel as defined in
Fig. 10. In flow circuit 3 (sensors 31, 32, 33), artificial CSF was
temporarily replaced by artificial CSF + 10% fresh blood as indicated
by the dotted lines. A nominal flow rate of 20 ml/h has been used.
After each position/orientation change of the sensor, a time of 15 min
was used to allow for a stabilization of the fluidic system before
measurement
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The viscosity of blood at 37°C in fluidic channels with
diameter bigger than 0.3 mm can reach values up to 3 times
of the viscosity of plasma (at a haematrocrit value of 0.45).
Blood as a non-newtonian fluid reaches viscosities η of
3.26 +/− 0.43, 4.37 +/− 0.60, and 5.46 +/− 0.84 mPa.s at
shear rates of 100, 50, and 1 s−1 at 37°C (Rosenson et al.
1996).
Compared to blood, the mean viscosity for plasma and
serum in healthy adults are significantly lower with values
of 1.39 +/− 0.08 mPa·s and 1.27 +/− 0.06 mPa·s respec-
tively. The same is true for CSF which is a newtonian fluid
reaching values in the range of 0.7–1 mPa·s at 37°C (Water:
η=0.65 mPa·s) (Bloomfield et al. 1998). Bloomfield et al.
investigated the effect of protein, erythrocytes and glucose
on the viscosity of CSF and its consequent impact on shunt
function. Protein concentration and viscosity values of CSF
from patients were measured relative to an artificial CSF
and distilled water values. The study concluded that
increased protein levels did not significantly increase CSF
viscosity.
Therefore the observed increase of flow rate in position
“Horizontal Sensor Blood UP 1/2” in Fig. 11 when blood is
added to artificial CSF in can be attributed to the change of
viscosity of the liquid due to the sedimentation of heavier
erythrocytes. The viscosity of this sediment becomes more
elevated resulting in a lower flow rate near the bottom of
the flow channel. Since the overall volume of the fluid
passing through the channel is kept constant by the
peristaltic pump, the flow rate at the top of the flow
channel, where only the lower viscous CSF-plasma mix is
flowing, increases accordingly. The decrease of flow rate in
position “Horizontal Sensor Blood DOWN” in Fig. 11 can
be explained by both a increased viscosity and reduced
thermal conductivity of the blood sediment.
4 Conclusions
We presented a novel implantable flow transducer which is
composed of a calorimetric flow sensor based on a thermal
anemometer principle, a microcontroller and a RF section
for passive telemetry and which can be implanted for the
treatment of hydrocephalus.
The in-vitro characterization of the transducer with
artificial CSF and artificial CSF where 10% fresh blood
was added did not show any drift which could be associated
to a deposition of proteins even though the tested protein
level of 2 g/l in CSF was about 10 times higher than the
normal protein level in human beings.
An offset of −2% to −10% with an average of −5.4%
which was found in the relative flow rate comparing the
sensor reading and the scale measurement is due to the
calibration of the sensors at room temperature versus the 37°C
test temperature.
A comparison of relative flow rates at 22°C and 37°C
gives a temperature offset of 6.3%. A temperature com-
pensation of the offset of −5.4% at 37°C with the
temperature offset of +6.3% leads to a compensated
average of all relative flow rates of +0.9%.
Even if a protein layer had been deposited on the flow
channel wall during the 26 days of exposure of the in-vitro
measurements, its thickness is not sufficient to have an
influence on the sensor reading.
Measurements with varying positions and orientations of
the sensor with respect to the flow channel indicate that
blood which is not homogeneously mixed in the CSF can
Fig. 13 Comparison of the flow
profile for artificial CSF (left)
and for artificial CSF with 10%
fresh blood (right). When fresh
blood is added to artificial CSF,
the erythrocytes settle down on
the bottom of the flow channel
which results in an asymmetric
flow profile
Fig. 12 Calibration curves of the CMOS calorimetric flow sensor for
water and methanol. The shape of the response curve of the sensor
strongly depends on the nonlinear influence of the thermal conduc-
tivity of the liquid used. The thermal conductivity of methanol is a
factor of 2.9 smaller compared to water
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temporarily disturb the flow sensor reading. However in a
real life situation this is not relevant as the patient is
moving and the fluid remains mixed. Blood did not create
any permanent changes of the sensor output due to
deposition of blood components on the flow channel wall.
The flow sensor specification requirement of +−10% for a
flow range between 2 ml/h and 40 ml/h. could be confirmed
at test conditions of 37°C.
When observing visually the transparent tubing of the
fluidic setup it was seen that the heavier blood components
(erythrocytes, thrombocytes) were settling on the tubing
bottom due to the low flow rate used. This sedimentation of
heavier blood components on the channel bottom means
that the viscosity of that sediment becomes more elevated
compared to the remaining CSF/plasma mix resulting in a
lower flow rate near the channel bottom. As the overall
volume of fluid passing through the channel is kept
constant by the peristaltic pump of the fluidic setup, the
top of the flow channel where only the lower viscous CSF/
plasma mix is remaining, the flow rate on top of the
sedimented erythrocytes increases (Fig. 13).
Most important, fresh blood added to the CSF with high
protein concentration of 2 g/l does not permanently
adsorbed onto the sensing surface: Comparing the relative
flow before the fresh blood was added and after the blood
was removed, the same accuracy between −5% and −9%
can be measured. That means that when the blood has
passed there is no permanent influence of the blood
remaining on the sensor reading. Furthermore this data
falls well within the accuracy of the sensors which is in the
range between −2% and −9%.
The addition of 10% fresh blood to artificial CSF leads
to an average increase of the relative flow rate of +17% —
compared to the scale reference measurement in the
configuration where the sensor is on the top of the flow
channel and to an averaged decrease of −53% compared to
the scale reference measurement in the configuration where
the sensor is at the bottom of the flow channel. The first
corresponds to the situation where the sensor is in contact
with a CSF/plasma mixture having an increased flow
velocity and the latter corresponds to the situation where
the sensor is in contact with the sedimented erythrocytes
solution having an increased viscosity and reduced thermal
conductivity. The observed asymmetry of relative flow rates
in horizontal up- and down positions can be explained by
the additional effect of reduced thermal conductivity of the
blood sediment which is effective only when the sensor is
in contact with the blood sediment in the horizontal down
position and which further reduces the sensor signal. The
velocity of the medium in vicinity to the sensing surface of
the anemometric flow sensor depends on the detailed
sedimentation profile of the mixture of artificial CSF and
10% whole blood.
The presented flow transducer has the potential to
improve the quality of life of normal pressure hydroceph-
alus patient, by more accurate monitoring of the functioning
of the valve and better understanding of CSF flow under
different physiological conditions. An improved manage-
ment of hydrocephalus shunted patients will be possible by
avoiding conditions of over- or under-drainage of CSF.
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